Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Last trade$8.60
Day change-$0.90 (-9.47%)
Day range$8.48 – $9.73
Volume940,534
Market cap$617M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$616.75M
Price / earnings
—
Price / book
2.19×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.42×
Profitability
Earnings per share
-$2.71
Return on assets
-54.6%
Return on equity
-62.61%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.43×
Quick ratio
7.43×
Cash ratio
2.2×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$165.47M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CGEM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$12.43M
$12.82M
$11.57M
$12.31M
$13.63M
$14.77M
$13.54M
$14.56M
Research and development
$40.17M
$44.44M
$42.12M
$42.95M
$41.97M
$61.03M
$41.46M
$40.49M
Total operating expenses
$52.6M
$57.25M
$53.7M
$55.26M
$55.6M
$75.8M
$55M
$55.05M
Operating income
-$52.6M
-$57.25M
-$53.7M
-$55.26M
-$55.6M
-$75.8M
-$55M
-$55.05M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$49.39M
-$53.7M
-$49.66M
-$50.71M
-$50.61M
-$70.06M
-$48.5M
-$47.53M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$117K
Net income
-$49.39M
-$53.7M
-$49.66M
-$50.71M
-$50.61M
-$70.06M
-$48.5M
-$47.65M
Net income attributable to common shareholders
-$47.87M
-$53.7M
-$45.49M
-$29.05M
-$45.61M
-$70.06M
-$43.7M
-$29.66M
EBITDA
-$52.55M
-$57.18M
-$53.62M
-$55.18M
-$55.52M
-$75.72M
-$54.92M
-$54.97M
Basic earnings per share
-$0.74
-$0.87
-$0.75
-$0.49
-$0.77
-$1.19
-$0.74
-$0.51
Diluted earnings per share
-$0.74
-$0.87
-$0.75
-$0.49
-$0.77
-$1.19
-$0.74
-$0.51
Recent news
Company coverage with links to the original publishers.
Cullinan Therapeutics announced positive Phase 1b/2a clinical data for velinotamig (GR1803), a BCMAxCD3 T cell engager, in patients with refractory systemic lupus erythematosus. Among 9 evaluable patients, 8 achieved clinically meaningful disease activity reduction, with 4 of 7 patients with elevated proteinuria achieving complete renal responses within 24 weeks. The drug demonstrated a favorable safety profile with no dose-limiting toxicities or serious adverse events.
Cullinan Therapeutics announced FDA and Australian regulatory clearance to initiate a Phase 1b/2a clinical trial of velinotamig, a BCMAxCD3 T cell engager, in patients with relapsing and refractory immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The study will evaluate the safety, tolerability, and clinical activity of the subcutaneous treatment designed to deplete antibody-producing plasma cells in these serious autoimmune blood disorders.
Cullinan Therapeutics announced the initiation of a New Drug Application (NDA) submission to the FDA for zipalertinib in combination with platinum-based chemotherapy for treating previously untreated EGFR exon 20 insertion NSCLC. The Phase 3 REZILIENT3 trial met its primary endpoint, demonstrating statistically significant improvement in median progression-free survival. The NDA submission is expected to be completed by year-end 2026 under the FDA's Real-Time Oncology Review program.
Cullinan Therapeutics announced that its CEO Nadim Ahmed and Chief Medical Officer Jeffrey Jones will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026. The company is a clinical-stage biopharmaceutical firm developing disease-modifying T cell engagers for autoimmune diseases and cancer.
Cullinan Therapeutics announced it will host a virtual event on September 14, 2026, to discuss Phase 3 REZILIENT3 trial results for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC. The trial met its primary endpoint of progression-free survival at the planned interim analysis, with results to be presented at the IASLC 2026 World Conference on Lung Cancer.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.